ISSN: 2451-0637
Archives of Medical Science - Civilization Diseases
Current volume Archive About the journal Abstracting and indexing Contact Instructions for authors Ethical standards and procedures

1/2021
vol. 6
 
Share:
Share:
more
 
 
abstract:
Clinical research

PNPLA3 gene polymorphism and severity of liver steatosis and fibrosis

Marta Wawrzynowicz-Syczewska
1
,
Aleksandra Waszczyk
1
,
Dorota Bander
1
,
Janusz Miętkiewski
2
,
Anna Urbańska
3
,
Kaja Scheibe
3

1.
Department of Infectious Diseases, Hepatology and Liver Transplantation, Pomeranian Medical University, Szczecin, Poland
2.
Department of Pathology, Marie-Curie Hospital, Szczecin, Poland
3.
Department of Infectious, Tropical Diseases and Immune Deficiency, Pomeranian Medical University, Szczecin, Poland
Arch Med Sci Civil Dis 2021; 6: e31–e35
Online publish date: 2021/04/20
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Introduction
Non-alcoholic fatty liver disease (NAFLD) is one of the leading chronic liver diseases worldwide. Environmental and genetic factors have an impact on NAFLD development. Single nucleotide polymorphism in the PNPLA3 gene is strongly related to the increased fat content in hepatocytes. The aim of our study was to investigate the association between PNPLA3 variants and the intensity of liver steatosis and fibrosis assessed by liver biopsy in patients with NAFLD.

Material and methods
The study group comprised 127 patients with NAFLD confirmed by liver biopsy. The control group comprised 251 healthy volunteers. In every case genotyping of the PNPLA3 rs738409 C to G nonsynonymous sequence variant was performed. Distributions of genotypes and alleles were compared between NAFLD patients and controls, and analyzed in relation to different steatosis and fibrosis stages in the study group.

Results
Frequencies of PNPLA3 genotypes strongly differ between NAFLD patients and controls (p = 0.00001). Odds ratio (OR) for genotype GG in NAFLD was 2.94 (1.45–5.97, p = 0.0015). Also allele G was more frequent in NAFLD patients vs. controls (p = 0.00001); OR for G allele in NAFLD was 2.74 (1.77–4.27, p = 0.00000273). No significant differences in the genotype or allele distribution of PNLPA3 were observed in relation to steatosis intensity or between patients with or without cirrhosis. However, allele G was found is every hepatocellular carcinoma case.

Conclusions
We do not advocate universal genetic testing in every NAFLD case to select patients at risk of development of cirrhosis or steatohepatitis. Further investigation of the relationship between PNPLA3 variants and hepatocellular carcinoma is warranted.

keywords:

fibrosis, steatosis, non-alcoholic fatty liver disease, patatin-like gene polymorphism

Quick links
© 2021 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe